vs
Side-by-side financial comparison of Cardiff Oncology, Inc. (CRDF) and Vir Biotechnology, Inc. (VIR). Click either name above to swap in a different company.
Cardiff Oncology, Inc. is the larger business by last-quarter revenue ($243.0K vs $240.0K, roughly 1.0× Vir Biotechnology, Inc.). Cardiff Oncology, Inc. runs the higher net margin — -2969.5% vs -67975.4%, a 65005.9% gap on every dollar of revenue. On growth, Cardiff Oncology, Inc. posted the faster year-over-year revenue change (62.0% vs -89.9%). Over the past eight quarters, Cardiff Oncology, Inc.'s revenue compounded faster (8.9% CAGR vs -88.0%).
Vir Biotechnology, Inc. is a clinical-stage immunology company focused on developing innovative therapies and vaccines to address serious infectious diseases including COVID-19, hepatitis B, HIV, and influenza. It operates primarily in the global biopharmaceutical market, collaborating with leading industry partners to advance its pipeline of targeted immune-based solutions for patient populations worldwide.
CRDF vs VIR — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $243.0K | $240.0K |
| Net Profit | $-7.2M | $-163.1M |
| Gross Margin | — | — |
| Operating Margin | -3221.0% | -72267.9% |
| Net Margin | -2969.5% | -67975.4% |
| Revenue YoY | 62.0% | -89.9% |
| Net Profit YoY | 38.8% | 23.7% |
| EPS (diluted) | $-0.11 | $-1.17 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $243.0K | — | ||
| Q3 25 | $120.0K | $240.0K | ||
| Q2 25 | $121.0K | $1.2M | ||
| Q1 25 | $109.0K | $3.0M | ||
| Q4 24 | $150.0K | $12.4M | ||
| Q3 24 | $165.0K | $2.4M | ||
| Q2 24 | $163.0K | $3.1M | ||
| Q1 24 | $205.0K | $56.4M |
| Q4 25 | $-7.2M | — | ||
| Q3 25 | $-11.3M | $-163.1M | ||
| Q2 25 | $-13.9M | $-111.0M | ||
| Q1 25 | $-13.4M | $-121.0M | ||
| Q4 24 | $-11.8M | — | ||
| Q3 24 | $-11.9M | $-213.7M | ||
| Q2 24 | $-11.8M | $-138.4M | ||
| Q1 24 | $-10.0M | $-65.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 99.1% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 97.9% | ||
| Q2 24 | — | 98.3% | ||
| Q1 24 | — | 99.9% |
| Q4 25 | -3221.0% | — | ||
| Q3 25 | -9978.3% | -72267.9% | ||
| Q2 25 | -12212.4% | -9754.3% | ||
| Q1 25 | -13194.5% | -4602.5% | ||
| Q4 24 | -8381.3% | — | ||
| Q3 24 | -7637.0% | -9718.7% | ||
| Q2 24 | -7696.3% | -5158.7% | ||
| Q1 24 | -5333.2% | -142.0% |
| Q4 25 | -2969.5% | — | ||
| Q3 25 | -9381.7% | -67975.4% | ||
| Q2 25 | -11523.1% | -9139.9% | ||
| Q1 25 | -12324.8% | -3989.6% | ||
| Q4 24 | -7858.0% | — | ||
| Q3 24 | -7184.8% | -8979.7% | ||
| Q2 24 | -7225.8% | -4500.1% | ||
| Q1 24 | -4883.4% | -115.8% |
| Q4 25 | $-0.11 | — | ||
| Q3 25 | $-0.17 | $-1.17 | ||
| Q2 25 | $-0.21 | $-0.80 | ||
| Q1 25 | $-0.20 | $-0.88 | ||
| Q4 24 | $-0.22 | — | ||
| Q3 24 | $-0.25 | $-1.56 | ||
| Q2 24 | $-0.26 | $-1.02 | ||
| Q1 24 | $-0.22 | $-0.48 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $58.3M | $497.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $45.4M | $796.1M |
| Total Assets | $61.9M | $1.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $58.3M | — | ||
| Q3 25 | $60.6M | $497.8M | ||
| Q2 25 | $71.0M | $598.7M | ||
| Q1 25 | $79.9M | $790.9M | ||
| Q4 24 | $91.7M | $901.0M | ||
| Q3 24 | $57.7M | $909.0M | ||
| Q2 24 | $60.3M | $1.1B | ||
| Q1 24 | $67.2M | $1.1B |
| Q4 25 | $45.4M | — | ||
| Q3 25 | $48.8M | $796.1M | ||
| Q2 25 | $58.6M | $947.5M | ||
| Q1 25 | $70.9M | $1.0B | ||
| Q4 24 | $82.9M | $1.2B | ||
| Q3 24 | $49.4M | $1.2B | ||
| Q2 24 | $52.4M | $1.4B | ||
| Q1 24 | $60.9M | $1.5B |
| Q4 25 | $61.9M | — | ||
| Q3 25 | $63.8M | $1.0B | ||
| Q2 25 | $75.7M | $1.2B | ||
| Q1 25 | $84.8M | $1.3B | ||
| Q4 24 | $97.2M | $1.4B | ||
| Q3 24 | $62.9M | $1.5B | ||
| Q2 24 | $66.1M | $1.7B | ||
| Q1 24 | $74.0M | $1.8B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-6.0M | $-167.6M |
| Free Cash FlowOCF − Capex | — | $-167.9M |
| FCF MarginFCF / Revenue | — | -69952.9% |
| Capex IntensityCapex / Revenue | — | 132.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-824.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-6.0M | — | ||
| Q3 25 | $-10.8M | $-167.6M | ||
| Q2 25 | $-8.3M | $-120.2M | ||
| Q1 25 | $-12.8M | $-78.1M | ||
| Q4 24 | $-10.3M | $-446.4M | ||
| Q3 24 | $-10.5M | $-171.5M | ||
| Q2 24 | $-9.2M | $-77.8M | ||
| Q1 24 | $-7.7M | $-109.4M |
| Q4 25 | — | — | ||
| Q3 25 | $-10.9M | $-167.9M | ||
| Q2 25 | — | $-122.8M | ||
| Q1 25 | — | $-79.7M | ||
| Q4 24 | — | $-453.7M | ||
| Q3 24 | — | $-174.2M | ||
| Q2 24 | — | $-78.5M | ||
| Q1 24 | $-7.8M | $-111.3M |
| Q4 25 | — | — | ||
| Q3 25 | -9043.3% | -69952.9% | ||
| Q2 25 | — | -10111.8% | ||
| Q1 25 | — | -2630.1% | ||
| Q4 24 | — | -3666.2% | ||
| Q3 24 | — | -7321.3% | ||
| Q2 24 | — | -2553.3% | ||
| Q1 24 | -3814.6% | -197.4% |
| Q4 25 | — | — | ||
| Q3 25 | 15.0% | 132.1% | ||
| Q2 25 | — | 209.1% | ||
| Q1 25 | — | 53.7% | ||
| Q4 24 | 0.0% | 59.0% | ||
| Q3 24 | 0.0% | 116.3% | ||
| Q2 24 | 0.0% | 21.7% | ||
| Q1 24 | 39.0% | 3.3% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
